参考文献/References:
[1] Kearney PM,Whelton M,Reynolds K,et al.Global burden of hypertension:analysis of worldwide data[J].Lancet,2005,365(9455):217-223.
[2] Williams B,Mancia G,Spiering W,et al.2018 ESC/ESH Guidelines for the management of arterial hypertension[J].Eur Heart J,2018,39(33):3021-3104.
[3] Schrader J,Lüders S,Kulschewski A,et al.Morbidity and mortality after stroke,eprosartan compared with nitrendipine for secondary prevention:principal results of a prospective randomized controlled study (moses)[J].Stroke,2005,36(6):1218-1226.
[4] Makkar KM,Sanoski CA,Spinler SA.Role of angiotensin-converting enzyme inhibitors,angiotensin ii receptor blockers,and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias[J].Pharmacotherapy,2009,29(1):31-48.
[5] Pareek M,Vaduganathan M,Biering-S?rensen T,et al.Pulse pressure,cardiovascular events,and intensive blood-pressure lowering in the systolic blood pressure intervention trial (sprint)[J].Am J Med,2019,132(6):733-739.
[6] Kelleher C,Hakimi Z,Zur R,et al.Efficacy and tolerability of mirabegron compared with antimuscarinic monotherapy or combination therapies for overactive bladder: A systematic review and network meta-analysis[J].Eur Urol,2018,74(3):324-333.
[7] Healey JS,Baranchuk A,Crystal E,et al.Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers:a meta-analysis [J].J Am Coll Cardiol,2005,45(11):1832-1839.
[8] Brunstr?m M,Carlberg B.Association of blood pressure lowering with mortality and cardiovascular disease across blood pressure levels:a systematic review and meta-analysis [J].JAMA Intern Med,2018,178(1):28-36.
[9] Julian Higgins JT. Cochrane handbook for systematic reviews of interventions,version 6.2,2021[M]. Cochrane Database of Systematic Reviews https://training.cochrane.org/handbook/current. 2021.
[10] Moher D,Liberati A,Tetzlaff J,et al.Preferred reporting items for systematic reviews and meta-analyses: The prisma statement[J].PLoS Med,2009,6(7):e1000097.
[11] Shamseer L,Moher D,Clarke M,et al.Preferred reporting items for systematic review and meta-analysis protocols (prisma-p) 2015:elaboration and explanation[J].BMJ,2015,350:g7647.
[12] Lumley T.Network meta-analysis for indirect treatment comparisons[J].Stat Med,2002,21(16):2313-2324.
[13] Zanchetti A,Bond MG,Hennig M,et al.Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis:principal results of the european lacidipine study on atherosclerosis (elsa),a randomized,double-blind,long-term trial[J].Circulation,2002,106(19):2422-2427.
[14] ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group.Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)[J].JAMA,2002,288(23):2981-2997.
[15] Borhani NO,Mercuri M,Borhani PA,et al.Final outcome results of the multicenter isradipine diuretic atherosclerosis study (midas). A randomized controlled trial[J].JAMA,1996,276(10):785-791.
[16] Brown MJ,Palmer CR,Castaigne A,et al.Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the international nifedipine gits study: Intervention as a goal in hypertension treatment (insight)[J].Lancet,2000,356(9227):366-372.
[17] Collier DJ,Poulter NR,Dahlof B,et al.Impact of amlodipine-based therapy among older and younger patients in the anglo-scandinavian cardiac outcomes trial-blood pressure lowering arm (ascot-bpla)[J].J Hypertens,2011,29(3):583-591.
[18] Dahl?f B,Devereux RB,Kjeldsen SE,et al.Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (life): A randomised trial against atenolol[J].Lancet,2002,359(9311):995-1003.
[19] Dahl?f B,Sever PS,Poulter NR,et al.Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required,in the anglo-scandinavian cardiac outcomes trial-blood pressure lowering arm (ascot-bpla):a multicentre randomised controlled trial [J].Lancet,2005,366(9489):895-906.
[20] Matsuoka H.A 12-month comparison of ace inhibitor and ca antagonist therapy in mild to moderate essential hypertension--the glant study. Study group on long-term antihypertensive therapy[J].Hypertens Res,1995,18(3):235-244.
[21] Hansson L,Lindholm LH,Ekbom T,et al.Randomised trial of old and new antihypertensive drugs in elderly patients:cardiovascular mortality and morbidity the swedish trial in old patients with hypertension-2 study[J].Lancet,1999,354(9192):1751-1756.
[22] Wright JT Jr,Bakris G,Greene T,et al.Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease:results from the aask trial[J].JAMA,2002,288(19):2421-2431.
[23] Julius S,Kjeldsen SE,Weber M,et al.Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine:the value randomised trial[J].Lancet,2004,363(9426):2022-2031.
[24] Kolloch R,Legler UF,Champion A,et al.Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease:findings from the international verapamil-sr/trandolapril study (invest)[J].Eur Heart J,2008,29(10):1327-1334.
[25] Lindholm LH,Ibsen H,Dahl?f B,et al.Cardiovascular morbidity and mortality in patients with diabetes in the losartan intervention for endpoint reduction in hypertension study (life): A randomised trial against atenolol[J].Lancet,2002,359(9311):1004-1010.
[26] Lithell H,Hansson L,Skoog I,et al.The study on cognition and prognosis in the elderly (scope):principal results of a randomized double-blind intervention trial[J].J Hypertens,2003,21(5):875-886.
[27] Liu L,Zhang Y,Liu G,et al.The felodipine event reduction (fever) study:a randomized long-term placebo-controlled trial in chinese hypertensive patients[J].J Hypertens,2005,23(12):2157-2172.
[28] Malacco E,Mancia G,Rappelli A,et al.Treatment of isolated systolic hypertension:the shell study results[J].Blood Press,2003,12(3):160-167.
[29] Matsuzaki M,Ogihara T,Umemoto S,et al.Prevention of cardiovascular events with calcium channel blocker-based combination therapies in patients with hypertension: A randomized controlled trial[J].J Hypertens,2011,29(8):1649-1659.
[30] Party MW.Medical research council trial of treatment of hypertension in older adults:principal results. Mrc working party[J].BMJ,1992,304(6824):405-412.
[31] Muramatsu T,Matsushita K,Yamashita K,et al.Comparison between valsartan and amlodipine regarding cardiovascular morbidity and mortality in hypertensive patients with glucose intolerance: Nagoya heart study[J].Hypertension,2012,59(3):580-586.
[32] Ogihara T,Matsuoka H,Rakugi H.Practitioner’s trial on the efficacy of antihypertensive treatment in elderly patients with hypertension Ⅱ (pate-hypertension Ⅱ study) in Japan[J].Geriatr Gerontol Int,2011,11(4):414-421.
[33] Ogihara T,Saruta T,Rakugi H,et al.Combinations of olmesartan and a calcium channel blocker or a diuretic in elderly hypertensive patients:a randomized,controlled trial[J].J Hypertens,2014,32(10):2054-2063 discussiom 63.
[34] Olsson G,Tuomilehto J,Berglund G,et al.Primary prevention of sudden cardiovascular death in hypertensive patients. Mortality results from the maphy study[J].Am J Hypertens,1991,4(2 Pt 1):151-158.
[35] Tatti P,Pahor M,Byington RP,et al.Outcome results of the fosinopril versus amlodipine cardiovascular events randomized trial (facet) in patients with hypertension and niddm[J].Diabetes Care,1998,21(4):597-603.
[36] Estacio RO,Jeffers BW,Hiatt WR,et al.The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension[J].N Engl J Med,1998,338(10):645-652.
[37] Rosei EA,Dal Palù C,Leonetti G,et al.Clinical results of the verapamil inhypertension and atherosclerosis study. Vhas investigators[J].J Hypertens,1997,15(11):1337-1344.
[38] Ruggenenti P,Lauria G,Iliev IP,et al.Effects of manidipine and delapril in hypertensive patients with type 2 diabetes mellitus:the delapril and manidipine for nephroprotection in diabetes (demand) randomized clinical trial[J].Hypertension,2011,58(5):776-783.
[39] Schrader J,Luders S,Kulschewski A,et al.Morbidity and mortality after stroke,eprosartan compared with nitrendipine for secondary prevention: Principal results of a prospective randomized controlled study (moses)[J].Stroke 2005,36(6):1218-1226.
[40] Baba S,J-MIND Study Group.Nifedipine and enalapril equally reduce the progression of nephropathy in hypertensive type 2 diabetics[J].Diabetes Res Clin Pract,2001,54(3):191-201.
[41] UK Prospective Diabetes Study Group.Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: Ukpds 39. Uk prospective diabetes study group[J].BMJ,1998,317(7160):713-720.
[42] Wachtell K,Lehto M,Gerdts E,et al.Angiotensin Ⅱ receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol:the losartan intervention for end point reduction in hypertension (life) study[J].J Am Coll Cardiol,2005,45(5):712-719.
[43] Wing LM,Reid CM,Ryan P,et al.A comparison of outcomes with angiotensin-converting--enzyme inhibitors and diuretics for hypertension in the elderly[J].N Engl J Med,2003,348(7):583-592.
[44] Yui Y,Sumiyoshi T,Kodama K,et al.Comparison of nifedipine retard with angiotensin converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease:the Japan multicenter investigation for cardiovascular diseases-b (JMIC-B) randomized trial[J].Hypertens Res,2004,27(3):181-191.
[45] Caldwell DM,Ades AE,Higgins JP.Simultaneous comparison of multiple treatments: Combining direct and indirect evidence[J].BMJ,2005,331(7521):897-900.
[46] Dias S,Welton NJ,Sutton AJ,et al.Evidence synthesis for decision making 1: introduction[J].Med Decis Making,2013,33(5):597-606.
[47] Wei J,Galaviz KI,Kowalski AJ,et al.Comparison of cardiovascular events among users of different classes of antihypertension medications:a systematic review and network meta-analysis [J].JAMA Netw Open,2020,3(2):e1921618.
[48] Suchard MA,Schuemie MJ,Krumholz HM,et al.Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes:a systematic,multinational,large-scale analysis[J].Lancet,2019,394(10211):1816-1826.
[49] Tobe SW,Clase CM,Gao P,et al.Cardiovascular and renal outcomes with telmisartan,ramipril,or both in people at high renal risk:results from the ontarget and transcend studies[J].Circulation,2011,123(10):1098-1107.
[50] Schiffrin EL,Deng LY,Larochelle P.Effects of a beta-blocker or a converting enzyme inhibitor on resistance arteries in essential hypertension[J].Hypertension,1994,23(1):83-91.
[51] Zhang Y,Sun N,Jiang X,et al.Comparative efficacy of β-blockers on mortality and cardiovascular outcomes in patients with hypertension:a systematic review and network meta-analysis [J].J Am Soc Hypertens,2017,11(7):394-401.
[52] 施仲伟,冯颖青,王增武,等.β受体阻滞剂在高血压应用中的专家共识[J].中华高血压杂志,2019,27(6):516-524.
相似文献/References:
[1]孙刚,黄冠华,综述.高血压合并心力衰竭的治疗策略[J].心血管病学进展,2016,(2):201.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.027]
SUN Gang,HUANG Guanhua.Treatment Strategy of Hypertension with Heart Failure[J].Advances in Cardiovascular Diseases,2016,(12):201.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.027]
[2]范贵娟,综述,徐瑞,等.盐敏感性高血压的研究进展[J].心血管病学进展,2016,(4):364.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.010]
FAN Guijuan,XU Rui.Research Progress of Salt Sensitive Hypertension[J].Advances in Cardiovascular Diseases,2016,(12):364.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.010]
[3]陈源源.钙通道阻滞剂在降压治疗中的应用[J].心血管病学进展,2015,(6):662.[doi:10.3969/j.issn.1004-3934.2015.06.002]
CHEN Yuanyuan.Application of Calcium Channel Blockers in Hypertension Treatment[J].Advances in Cardiovascular Diseases,2015,(12):662.[doi:10.3969/j.issn.1004-3934.2015.06.002]
[4]张瑞 毛露 孙硕 Dirk Hermann 陈艾东.内皮素-1干预成为高血压治疗新靶点的展望[J].心血管病学进展,2019,(7):969.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.000]
ZHANG Rui MAO LuSUN ShuoDIRK Hermann CHEN Aidong.The Prospect of Endothelin-1 Intervention as A New Target for the Treatment of Hypertension[J].Advances in Cardiovascular Diseases,2019,(12):969.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.000]
[5]张毅,柳志红.动态血压监测在高血压中的应用现状与问题[J].心血管病学进展,2019,(6):848.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.003]
ZHANG Yi,LIU Zhihong.Current status and nsolved Pproblems of Ambulatory Blood Pressure Monitoring for the Management of Hypertension[J].Advances in Cardiovascular Diseases,2019,(12):848.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.003]
[6]黄秋瑾 胡蓉.高血压合并糖尿病患者血压控制率和控制目标的探讨[J].心血管病学进展,2019,(7):973.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.002]
HUANG QiujinHU Rong.Discussion on Blood Pressure Control Rate and Control Target in Patients with Hypertension Complicated with Diabetes[J].Advances in Cardiovascular Diseases,2019,(12):973.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.002]
[7]张旭明 王曦.高血压对认知功能的影响[J].心血管病学进展,2019,(7):977.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.003]
ZHANG Xuming,WANG Xi.The Relationship Between Hypertension and Cognitive Function[J].Advances in Cardiovascular Diseases,2019,(12):977.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.003]
[8]凌梦军 陈明凌梦军.阻塞性睡眠呼吸暂停低通气综合征与高血压关系的研究进展[J].心血管病学进展,2019,(5):722.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.015]
[9]李波 郭毅 田进文 邓珏琳.高血压合并2型糖尿病的治疗进展[J].心血管病学进展,2019,(9):1196.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.002]
LI Bo,GUO Yi,TIAN Jinwen,et al.Therapy in Hypertensive Patients with Type 2 Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2019,(12):1196.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.002]
[10]王继航 赵施皓 李开亮 田进文 李玉龙 付士辉 沈明志 邓珏琳.远程医疗在高血压病管理中的研究进展[J].心血管病学进展,2019,(9):1199.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.003]
WANG Jihang,ZHAO Shihao,LI Kailiang,et al.Telemedicine in Hypertension Management[J].Advances in Cardiovascular Diseases,2019,(12):1199.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.003]